Replimune Group is expected to report a fiscal loss of $0.73 per share on consensus revenue of $0.95 million, with the current stock price of $11.63 trading well above the average analyst price target of $8.17.
Investors are primarily focused on the regulatory trajectory of the lead oncolytic immunotherapy, RP1, following the FDA's acceptance of its Biologics License Application resubmission for advanced melanoma.
The agency has established an August 2, 2026 PDUFA goal date and expects an advisory committee meeting in late July. While clinical durability data from the IGNYTE trial is encouraging, concerns persist regarding the company’s cash runway, which is projected to sustain operations only into early 2027.